- Home
- BCAL vs CELC Comparison
BCAL vs CELC Comparison
Compare BCAL & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAL
- CELC
- Stock Information
- Founded
- BCAL 2001
- CELC 2011
- Country
- BCAL United States
- CELC United States
- Employees
- BCAL N/A
- CELC N/A
- Industry
- BCAL Major Banks
- CELC Medical Specialities
- Sector
- BCAL Finance
- CELC Health Care
- Exchange
- BCAL Nasdaq
- CELC Nasdaq
- Market Cap
- BCAL 519.9M
- CELC 440.0M
- IPO Year
- BCAL N/A
- CELC 2017
- Fundamental
- Price
- BCAL $16.84
- CELC $51.63
- Analyst Decision
- BCAL Buy
- CELC Strong Buy
- Analyst Count
- BCAL 2
- CELC 5
- Target Price
- BCAL $19.50
- CELC $53.60
- AVG Volume (30 Days)
- BCAL 82.4K
- CELC 1.1M
- Earning Date
- BCAL 10-28-2025
- CELC 08-14-2025
- Dividend Yield
- BCAL N/A
- CELC N/A
- EPS Growth
- BCAL 15.70
- CELC N/A
- EPS
- BCAL 0.99
- CELC N/A
- Revenue
- BCAL $157,669,000.00
- CELC N/A
- Revenue This Year
- BCAL $71.01
- CELC N/A
- Revenue Next Year
- BCAL $2.69
- CELC N/A
- P/E Ratio
- BCAL $16.88
- CELC N/A
- Revenue Growth
- BCAL 80.55
- CELC N/A
- 52 Week Low
- BCAL $11.87
- CELC $7.58
- 52 Week High
- BCAL $18.49
- CELC $55.44
- Technical
- Relative Strength Index (RSI)
- BCAL 63.80
- CELC 76.90
- Support Level
- BCAL $15.86
- CELC $48.73
- Resistance Level
- BCAL $17.00
- CELC $55.44
- Average True Range (ATR)
- BCAL 0.37
- CELC 2.65
- MACD
- BCAL 0.10
- CELC -0.78
- Stochastic Oscillator
- BCAL 87.43
- CELC 88.28
About BCAL Southern California Bancorp
California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through partnerships with its clients. The company has one operating segment: Commercial Banking.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.